Gadolinium-based contrast Agents (GBCAs) used during magnetic resonance imaging (MRI) may leave deposits of gadolinium, a type of heavy metal, in the brain and other body tissues, but there is no evidence that gadolinium retention in the brain from any of the GBCAs is harmful, the Food and Drug Administration (FDA) announced in a Safety Communication. As a result, the agency said there is no evidence to suggest the use of GBCA should be restricted at this time. “We will continue to assess the safety of GBCAs and plan to have a public meeting to discuss this issue in the ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.